Minerals Technologies Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended April 3, 2022; comparisons are with the three months ended April 4, 2021. Minerals Technologies develops and sells specialty minerals, mineral-based and synthetic products, and related systems and services through Performance Materials, Specialty Minerals, and Refractories.
Financial performance
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Net sales | $519.1 million | $452.6 million | +15% |
| Production margin | $121.7 million; 23.4% | $111.8 million; 24.7% | Margin down 1.3 percentage points |
| Operating income | $66.2 million; 12.8% margin | $58.8 million; 13.0% margin | +13% |
| Net income attributable to MTI | $44.1 million | $39.9 million | +11% |
| Diluted EPS | $1.33 | $1.17 | Up $0.16 |
| Operating cash flow | $0.3 million | $50.9 million | Down $50.6 million |
Cost of sales rose 17%, faster than sales, primarily due to higher raw material, energy, and manufacturing costs. Management said pricing actions lagged cost increases, pressuring production margin. The effective tax rate increased to 20.0% from 18.0%, primarily due to higher withholding taxes on dividends. Acquisition-related transaction and integration costs were $1.6 million.
Segments and key changes
- Performance Materials: Sales rose 18% to $272.1 million; operating income increased 13% to $33.7 million. Household, Personal Care & Specialty Products sales benefited from strong consumer demand and $27.7 million of Normerica sales. Environmental Products grew with increased project activity; Metalcasting sales fell 2%, primarily due to temporarily lower demand in China.
- Specialty Minerals: Sales rose 10% to $163.1 million, but operating income fell 13% to $18.4 million and segment margin decreased to 11.3% from 14.3%. Management cited inflationary costs outpacing the timing of price increases.
- Refractories: Sales increased 14% to $83.9 million and operating income rose 38% to $16.5 million. Management attributed stronger margins to pricing actions and operational efficiencies.
Sales growth reflected stronger demand across segments, continued pricing actions, and the Normerica acquisition. Foreign exchange reduced sales by approximately $16 million, or four percentage points. U.S. sales rose 19%; international sales rose 11%.
Cash, liquidity, and debt
- Cash and cash equivalents were $288.0 million at April 3, 2022, versus $299.5 million at year-end; short-term investments were $5.1 million. Management reported total available liquidity of more than $450 million, including cash and revolver availability.
- Operating cash flow was only $0.3 million, versus $50.9 million a year earlier. Management attributed the decline primarily to a planned inventory build and higher accounts receivable associated with pricing. Capital expenditures were $19.0 million; cash decreased by $11.5 million during the quarter.
- Short-term debt was $110.0 million and long-term debt, including current maturities, was approximately $937.6 million. The $300 million revolving facility had $110.0 million of loans and $10.0 million of letters of credit outstanding; the company reported covenant compliance. The term loan tranche is due in 2024; $400 million of senior notes bearing 5.0% interest are due in 2028.
- Management expected 2022 capital expenditures of $80 million to $85 million, principally for PCC plants and other strategic growth projects. The company repurchased $16.7 million of shares during the quarter; its $75 million authorization had $46.5 million remaining at quarter-end.
Outlook, risks, and unusual items
The filing provides no specific earnings or sales forecast. Management described demand as improving in many end markets and outlined growth priorities including pet care, environmental remediation products, paper and packaging applications, construction markets, and refractory products, alongside selective acquisitions and operational improvements. Management cautioned that there is no assurance these initiatives will succeed.
Normerica, acquired in July 2021 for net consideration of $187.5 million, contributed $27.7 million of quarterly sales. Its purchase price allocation remained preliminary, with completion expected in the third quarter of 2022. Acquisition integration and transaction costs were $1.6 million in Q1.
Key stated risks include inflation in raw materials, energy and shipping; customer and end-market cyclicality; foreign exchange and variable interest rates; debt service and covenant requirements; global supply and operating disruptions; and regulatory, environmental, tax, and product-liability matters. Management said COVID-19 was not materially affecting current results but could not estimate future impacts. The company reported 342 open asbestos cases related to talc products and operations; management said the potential liability was not expected to materially affect financial position or results, while noting that claim amounts could not be determined from the pleadings. The interim financial statements were reviewed by KPMG, not audited.
Investor verification priorities
- Whether pricing actions catch up with cost inflation and restore production and operating margins.
- Whether the inventory build and higher receivables convert into improved operating cash flow.
- Normerica’s final purchase-price allocation, integration progress, and expected contribution beyond reported sales.
- Liquidity and refinancing plans ahead of the 2024 term-loan maturity, and continued compliance with debt covenants.
- Developments in asbestos litigation, including defense costs, indemnification coverage, and any change in management’s materiality assessment.
- Progress toward the stated $80–$85 million 2022 capital-spending plan and growth initiatives; the filing does not give quantified earnings guidance.